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Abstract
The reports on the origin of human CD8
+ Va24
+ T-cell receptor (TCR) natural killer T (NKT) cells are controversial. The
underlying mechanism that controls human CD4 versus CD8 NKT cell development is not well-characterized. In the present
study, we have studied total 177 eligible patients and subjects including 128 healthy latent Epstein-Barr-virus(EBV)-infected
subjects, 17 newly-onset acute infectious mononucleosis patients, 16 newly-diagnosed EBV-associated Hodgkin lymphoma
patients, and 16 EBV-negative normal control subjects. We have established human-thymus/liver-SCID chimera,
reaggregated thymic organ culture, and fetal thymic organ culture. We here show that the average frequency of total
and CD8
+ NKT cells in PBMCs from 128 healthy latent EBV-infected subjects is significantly higher than in 17 acute EBV
infectious mononucleosis patients, 16 EBV-associated Hodgkin lymphoma patients, and 16 EBV-negative normal control
subjects. However, the frequency of total and CD8
+ NKT cells is remarkably increased in the acute EBV infectious
mononucleosis patients at year 1 post-onset. EBV-challenge promotes CD8
+ NKT cell development in the thymus of human-
thymus/liver-SCID chimeras. The frequency of total (3% of thymic cells) and CD8
+ NKT cells (,25% of NKT cells) is
significantly increased in EBV-challenged chimeras, compared to those in the unchallenged chimeras (,0.01% of thymic
cells, CD8
+ NKT cells undetectable, respectively). The EBV-induced increase in thymic NKT cells is also reflected in the
periphery, where there is an increase in total and CD8
+ NKT cells in liver and peripheral blood in EBV-challenged chimeras.
EBV-induced thymic CD8
+ NKT cells display an activated memory phenotype (CD69
+CD45RO
hiCD161
+CD62L
lo). After EBV-
challenge, a proportion of NKT precursors diverges from DP thymocytes, develops and differentiates into mature CD8
+ NKT
cells in thymus in EBV-challenged human-thymus/liver-SCID chimeras or reaggregated thymic organ cultures. Thymic
antigen-presenting EBV-infected dendritic cells are required for this process. IL-7, produced mainly by thymic dendritic cells,
is a major and essential factor for CD8
+ NKT cell differentiation in EBV-challenged human-thymus/liver-SCID chimeras and
fetal thymic organ cultures. Additionally, these EBV-induced CD8
+ NKT cells produce remarkably more perforin than that in
counterpart CD4
+ NKT cells, and predominately express CD8aa homodimer in their co-receptor. Thus, upon interaction with
certain viruses, CD8 lineage-specific NKT cells are developed, differentiated and matured intrathymically, a finding with
potential therapeutic importance against viral infections and tumors.
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Introduction
NKT cells are unconventional T cells that bridge the innate and
adaptive immune systems [1–4]. Unlike conventional T cells,
which recognize MHC-molecule-presented peptide antigens via
their abTCR, NKT cells recognize CD1d-presented glycolipids.
Two subsets of functionally distinct CD1d-dependent NKT cells
have been identified based on whether the cells express the semi-
invariant Va24-Ja18 TCR (Va14-Ja18 in mice) [1,2,5–12] and
whether they recognize the exogenous NKT cell ligand a-GalCer.
Other NKT-like cells have been reported based on their CD1d-
independence and CD161 (NK1.1 in mouse) or CD56 expression
[12–16], or other semi-invariant Va7.2-Ja33/Vb2,13 TCR
expression (Va19/Vb6,8 in mouse) [12].
In mice, conventional abT cell development in the thymus
proceeds through three major stages, i.e. CD4
2CD8
2 (DN),
CD4
+CD8
+ (DP), and CD4
+CD8
2 or CD4
2CD8
+ (SP) [17]. The
developing abT cells undergo positive and negative selection
based on TCR affinity of MHC expressed on antigen presenting
cells. By contrast, the semi-invariant abTCR DP NKT precursors
interact with the CD1d-ligand complex either on cortical
thymocytes to undergo positive selection [1–2], or on thymic
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selected DP NKT cell precursors mature by down-regulating CD8
to reach a CD4
+CD44
lo stage [1–2]. Unlike conventional T cells,
which emigrate from the thymus as naı ¨ve cells, CD44
lo NKT cells
remain in the postnatal thymus and undergo a linear differenti-
ation program including the expression of the terminal differen-
tiation marker NK1.1 [19,20]. However, a proportion of the
immature NKT cells remains NK1.1
2 and leaves the thymus
[19,20]. The final NKT-differentiation step takes place in both
thymus and periphery [21,22]. Peripheral NKT cells reside
preferentially in the liver [23,24], but are also present in the
spleen, lymph nodes, bone marrow, lung, and gut [1,2]. Human
NKT cells have not been detected in engrafted fetal thymus tissue
in a hu-thy/liv-SCID model, leading to a presumption that the
development of peripheral NKT cells is thymus independent [25].
In later studies, it was proposed that the human thymus has little
or no role in generating peripheral NKT cells after birth. This
hypothesis is based on the inverse correlation between NKT cell
frequency in fetal thymus and gestational age, and on the lack of a
clear NKT cell population in postnatal thymus but their definite
presence in adult blood [26–28]. However, reports on the origin of
human CD8
+ Va24
+TCR NKT cells are still controversial.
In mice, it is believed that there are essentially no CD8
+ NKT
cells [1,2,29]. However, recent report shows that IL-15 expands
CD8aaNK1.1
+ cells [30]. In humans, the existence of CD8
+
NKT cells in thymus and periphery is an area of controversy.
CD8
+ abTCR NKT cells expressing CD8aa homodimer are
reported in human PBMC [31]. While there are several reports
questioning the existence of these cells [26,32], it is widely
believed that CD8 is expressed on a minor proportion of human
NKT cells, and that the CD8 marker is usually acquired after
egress from the thymus [27,28,33–37]. The finding of a limited
correlation between human thymic CD4
+ NKT cells and
peripheral CD8
+ NKT cells has raised the question of what is
the origin of CD8
+ NKT cells [27,28]. As accumulation of
findings on NKT cell development, the underlying mechanisms
that control CD4-CD8 differentiation of human NKT cells are
becoming better characterized.
Results
EBV-induced CD8
+ NKT cells in various EBV-infected
individuals
We studied 177 eligible patients and subjects including 128
healthy latent EBV-infected subjects [EBV
+(La)], 17 newly-onset
acute infectious mononucleosis patients [EBV
+(IMa)], 16 newly-
diagnosed EBV-associated Hodgkin lymphoma patients
[EBV
+(HL)], and 16 EBV-negative normal control subjects (NS)
(Table S1). None of the individuals had received treatment with
anti-virals, antibiotics, or corticosteroids before entry into this
study. The race of all individuals was Han as determined and
registered by the physicians in this study. None of the individuals
had other complicating clinical infectious symptoms when the
study samples were taken. The average frequency of total NKT
cells in PBMCs from the 128 EBV
+(La) subjects (1.560.5%) was
significantly higher than that from 16 EBV-negative NS subjects
(0.1860.2%), 17 new-onset EBV
+(IMa) patients (0.1560.1%) and
16 newly-diagnosed EBV
+(HL) patients (0.160.1%) (Figure 1B).
The frequency of total NKT cells in the EBV
+(IMa) patients
dramatically increased at year 1 post-onset [EBV
+(IMy),
1.660.6%] (Figure 1B). The frequency of the CD8
+ subset of
NKT cells in PBMCs from the EBV
+(La) subjects (1764%) was
remarkably higher than from EBV-negative NS subjects
(2.160.3%), new-onset EBV
+(IMa) patients (1.960.4%) and
EBV
+(HL) patients (1.160.2%) (Figure 1B). The frequency of
CD8
+ NKT cells in the EBV
+(IMa) patients was significantly
increased at year 1 post-onset [EBV
+(IMy), 2065%] (Figure 1B).
However, the average frequencies of total T cells and the ratios of
CD4
+ versus CD8
+ T cells in PBMCs among the EBV
+(La),
EBV
+(HL), EBV
+(IMy) and NS subjects were not significantly
different (Figure 1C), except for a slight and temporary increase in
the frequency of total T cells in the EBV
+(IMa) patients (Figure 1C,
some data not shown). These observations clearly indicate that the
EBV status affects the frequency of NKT cells, particularly, the
appearance of CD8
+ NKT cells in PBMC.
EBV induces intrathymic CD8
+ NKT cell development
To investigate the mechanism of total and CD8-lineage
differentiation of human NKT cells in the context of EBV, we
established hu-thy/liv-SCID chimeras. The chimeras were
challenged i.t. with EBV, a dsDNA virus, or with human T-cell
leukaemia virus type 1 (HTLV-1), a retrovirus. The EBV-
challenge efficiently promoted the generation of total NKT cells,
whereas HTLV-1-challenge had no effect, but instead promoted a
significant increase in the frequency of abTCR thymocytes and
spleen T cells (Figure 2A). The frequency of total NKT cells
reached more than 3% of thymic cells and more than 2% of
hepatic cells by week 5 post-challenge with EBV. By contrast, the
total thymic and hepatic NKT cells were less than 0.01% within 5
weeks post-challenge with HTLV-1, comparable to the frequen-
cies in unchallenged chimeras (Figure 2A). The frequencies of total
thymic or hepatic T cells at week 5 were slightly but significantly
increased following HTLV-1 infection. There were approximately
30,000–35,000 total NKT cells per million thymic cells, and
20,000–23,000 total NKT cells per million hepatic cells at week 5
in EBV-challenged chimeras (Table S2). The EBV-challenge did
not significantly alter the generation of total mainstream abT cells,
whereas HTLV-1-challenge did promote the generation of the T
cells, compared with those in unchallenged chimeras (Figure 2B).
The frequency of total T cells reached ,28% of thymic cells and
,32% of spleen cells at week 5 in the chimeras challenged with
EBV or HTLV-1, as well as in the unchallenged chimeras
(Figure 2B). Cell phenotyping based on CD4 and CD8 expression
Author Summary
We show that the average frequency of total and CD8
+
NKT cells in PBMCs from 128 healthy latent EBV-infected
subjects is significantly higher than in 17 patients with
acute lytic EBV infection, 16 EBV-associated HL patients,
and 16 EBV-negative normal subjects. The frequency of
total and CD8
+ NKT cells is remarkably increased in the
lytic EBV-infected patients at year 1 post-onset. EBV-
challenge promotes total and CD8
+ NKT cell development
in the thymus and liver of human-thymus/liver-SCID
chimeras, compared to those in the unchallenged
chimeras. After EBV-challenge, a proportion of NKT
precursors diverges from DP thymocytes, develops and
differentiates into mature CD8
+ NKT cells in thymus in EBV-
challenged human-thymus/liver-SCID chimeras or reaggre-
gated thymic organ cultures. Thymic EBV-infected den-
dritic cells are required for this process. IL-7 is an essential
factor for CD8
+ NKT cell differentiation. EBV-induced CD8
+
NKT cells produce remarkably more perforin, and predom-
inately express CD8aa homodimer. CD8 lineage-specific
NKT cells are developed and differentiated intrathymically
upon EBV-exposure, a finding with potential therapeutic
importance against viral infections and tumors.
EBV-Induced CD8
+ NKT Cell Development
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the generation of thymic CD8
+ NKT cells and the appearance of
hepatic CD8
+ NKT cells in the chimeras transplanted i.t. with
total thymocytes (NKT cell-depleted) plus thymic stromal cells, a
population that includes DC (Figure 2E), compared to unchal-
lenged chimeras (Figure 2D). By contrast, HTLV-1-challenge had
no effect on the frequency of CD8
+ NKT cells (data not shown).
The frequency of CD8
+ cells in the chimeras reached more than
25% of thymic NKT cells and more than 23% of hepatic NKT
cells at week 5 post-EBV challenge (Figure 2E). The CD8
+ cells
were essentially undetectable among thymic and hepatic NKT
cells at 5 weeks in the unchallenged chimeras (Figure 2D). The
different thymic or hepatic NKT cell populations (DN, CD4
+, and
CD8
+) in the HTLV-1-challenged chimeras were comparable to
those in the unchallenged chimeras (data not shown). The
frequencies of total and CD4/CD8 co-receptor-expressing NKT
cells in peripheral blood correlated well with those in thymus and
livers in both unchallenged and EBV-challenged hu-thy/liv-SCID
chimeras (data not shown). An important role for DCs in the
generation of thymic and hepatic CD8
+ NKT cells is suggested by
the finding that the frequency of these cells was rather low in both
unchallenged and EBV-challenged chimeras transplanted i.t. with
total fetal thymocytes plus DC-depleted thymic stromal cells (data
not shown), an issue explored further below. The different thymic
and spleen co-receptor-expressing mainstream T cells (DN,
CD4
+CD8
lo, CD4
+, CD8
+) in the EBV- or HTLV-1-challenged
chimeras were comparable to those in the unchallenged chimeras
(Figure 2D, 2E, and some data not shown). The absolute numbers
Figure 1. Human NKT and T cells in the various EBV-infected and non-infected subjects. (A) The experimental and analysis scheme for
detecting co-receptor-expressing NKT cells and T cells in PBMC was illustrated. The data to establish negative staining gates with fluorochrome
conjugated empty CD1d tetramers (eCD1d tetramer) and abTCR isotype mAb (abTCRIso) control was shown in rightmost panel of this subfigure. (B)
and (C) Frequencies of total (left panel) and co-receptor-expressing (right panel) NKT (B) and conventional abT cells (C) in PBMCs from healthy latent
EBV-infected subjects [EBV
+(La)], newly-onset acute infectious mononucleosis patients [EBV
+(IMa)], IM patients at year 1 post-onset [EBV
+(IMy)], EBV-
associated HL patients [EBV
+(HL)] and EBV-negative normal control subjects (NS) assessed by flow cytometry. The absolute numbers per ml of NKT
cell subsets of various patient and subject were shown in bottom panel as means 6 s.d. (the s.d. was not shown for simplicity of the figure) (B). Data
were mean 6 s.d. (For patient numbers see Table S1). *, p,0.001.
doi:10.1371/journal.ppat.1000915.g001
EBV-Induced CD8
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various hu-thy/liv-SCID chimers were shown in the Table S2.
Thymic CD8
+ NKT cells from EBV-challenged hu-thy/liv-
SCID chimeras displayed an activated memory phenotype
(CD69
+CD45RO
hi), compared with thymic CD4
+ NKT cells in
same chimeras (Figure S1A). Hepatic CD8
+ NKT cells expressed
higher amounts of CD62L than thymic CD8
+ NKT cells in the
EBV-challenged chimeras, probably attributable to their egress
from the thymus toward secondary lymphoid organs, whereas
these hepatic CD8
+ NKT cells expressed similar amounts of CD69
Figure 2. EBV promotes CD8
+ NKT cell development in vivo in hu-thy/liv-SCID chimeric mice. (A) and (B) Development of total NKT (A)
and T cells (B). The frequencies of NKT cells and T cells in thymus, liver, and spleen from hu-thy/liv-SCID chimeras challenged i.t. with EBV (EBV
+)o r
HTLV-1 (HTLV-1
+), were assessed by flow cytometry (middle and right panels) at the indicated timepoints. Unchallenged hu-thy/liv-SCID chimeras (Nil)
were used as controls. Empty CD1d tetramer and isotype matched control Abs, which were used as staining controls, were not illustrated in this
figure. The experimental and analysis scheme was shown in the leftmost panel. Data were mean 6 s.d. (n = 8). *, p,0.001. EBV-challenged chimeras
vs. non-challenged or HTLV-1-challenged chimeras. (C) The experimental and analysis scheme for detecting the co-receptor-expressing NKT cells and
T cells in various organs from different hu-thy/liv-SCID chimeras was illustrated. The a-GalCer-loaded CD1d tetramer, abTCR mAb and other relevant
mAbs were used to identify the different subsets of NKT cells and T cells as illustrated. The appropriate isotype Abs and empty fluorochrome-
conjugated CD1d tetramer were used as controls. (D) and (E) Data showed the frequencies of co-receptor-expressing NKT cells and T cells in the
unchallenged (D, Nil) or EBV challenged (E, EBV) hu-thy/liv-SCID chimeras. The protocols for the establishment of the chimeras were described in the
leftmost panels. The chimeras were sacrificed at the indicated time intervals following post-immune-reconstitution and viral challenge and the
various organs and tissues were collected. +DC, thymic DCs were included. VL, very low level (below detectable levels). Data were mean 6 s.d. (n =
7). *, p,0.001, EBV-challenged chimeras vs. non-challenged or HTLV-1-challenged chimeras.
doi:10.1371/journal.ppat.1000915.g002
EBV-Induced CD8
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+ NKT cells (data not shown).
CD161, a maturation marker for human NKT cells, was
uniformly highly expressed on thymic and hepatic CD8
+ NKT
cells in EBV-challenged chimeras; the frequency of CD8
+ NKT
cells in the unchallenged chimeras was too low to evaluate CD161
expression. On CD4
+ NKT cells, CD161 expression was
independent of EBV challenge and revealed two populations,
CD161
hi and CD161
lo, although the former population expressed
much higher levels of CD161 in the EBV treated mice (Figure S1A
and some data not shown). In parallel, we also examined the
expression of CD69, CD62L and CD45RO on thymic and
spleenic CD4
+, CD4
+CD8
lo, CD4
+CD8
+, and CD8
+ T cells in
EBV-challenged or unchallenged chimeras. Both CD4
+ and CD8
+
T cells in thymus and spleen from EBV-challenged hu-thy/liv-
SCID chimeras displayed an activated memory phenotype
(CD69
+CD45RO
hi), compared with T cells from unchallenged
chimeras (Figure S2B and some data not shown). Spleen CD4
+
and CD8
+ T cells in EBV-challenged chimeras expressed higher
amounts of CD62L (data not shown) than the thymic CD4
+ and
CD8
+ T cells (Figure S1B), which might be attributable to their
egress from the thymus to secondary lymph organs.
EBV-induced CD8
+ NKT cell development depends on
thymic DCs
We established different hu-thy/liv-SCID chimeras by i.t.
transplantation with purified human fetal DP thymocytes plus
thymic stromal cells (either DC-containing or DC-depleted). In
chimeras transplanted DN thymocytes only, the frequency of total
NKT cells was very low (,0.01% of thymic or hepatic cells) at
week 5 in both unchallenged and EBV-challenged mice (Figure 3B,
3C). The great majority of cells were CD4-expressing in both
chimeras. Less than 0.5% of thymic and hepatic CD8
+ NKT cells
were detected in EBV-challenged chimeras (Figure 3C). Both the
frequency of total abTCR-expressing T cells and the ratio of
CD4
+ to CD8
+ T cells in thymus and spleen from EBV-challenged
hu-thy/liv-SCID chimera transplanted with DP thymocytes only
(Figure 3B, 3C) were comparable to those in EBV-challenged or
unchallenged chimeras transplanted with total thymocytes
(Figure 2). We further examined the ontogeny and distribution
of NKT cells and T cells in hu-thy/liv-SCID chimeras
transplanted i.t. with fetal DP thymocytes plus DC-containing
thymic stromal cells. The frequency of total NKT cells was still
rather low (,0.02% of thymic or hepatic cells) at week 5 post-
establishment in the unchallenged chimeras (Figure 3D), but was
substantially increased (,3% of thymic or hepatic cells) at week 5
post-establishment in EBV-challenged chimeras (Figure 3E). Up to
25% of thymic or hepatic NKT cells expressed CD8 in EBV-
challenged chimeras, whereas the frequencies of thymic or hepatic
CD4
+ NKT cells were correspondingly lower than those in the
unchallenged chimeras (Figure 3D, 3E). The frequency of total
mature abTCR-expressing T cells and the ratio of CD4
+ to CD8
+
T cells in thymus and spleen in EBV-challenged hu-thy/liv-SCID
chimeras were comparable to those in unchallenged chimeras
(Figure 3D, 3E). The development of thymic or hepatic CD8
+
NKT cells was severely impaired by the DC-deletion. The
frequency of thymic and hepatic CD8
+ NKT cells was essentially
below the level of detection in both unchallenged and EBV-
challenged chimera transplanted i.t. with DP thymocytes plus DC-
depleted thymic stromal cells (Figure 3F, 3G). We also examined
the ontogeny and distribution of NKT cells and T cells in the hu-
thy/liv-SCID chimeras transplanted i.t. with DP thymocytes plus
purified thymic DC. The frequency of total thymic and hepatic
NKT cells and the ratio of CD4
+ to CD8
+ NKT cells in EBV-
challenged or unchallenged chimeras were comparable to those in
the counterpart chimeras transplanted with DP thymocytes plus
DC-included thymic stromal cells (data not shown). We further
established hu-thy/liv-SCID chimeras by transplantation i.t. with
fetal DP thymocytes plus i.v. syngeneic fetal BM-derived DCs. The
frequency of total NKT cells was substantially increased to ,2%
of thymic or hepatic cells at week 5 post-establishment in the EBV-
challenged chimeras (Figure 3I), compared to the unchallenged
chimeras (,0.01% of thymic or hepatic cells) (Figure 3H). Up to
23% of thymic and hepatic NKT cells expressed CD8 in the EBV-
challenged chimeras, whereas the levels of thymic and hepatic
CD4
+ NKT cells were correspondingly lower than those in the
unchallenged chimeras (Figure 3H, 3I). The frequency of total
mature abTCR-expressing T cells and the ratio of CD4
+ to CD8
+
T cells in thymus and spleen from EBV-challenged hu-thy/liv-
SCID chimeras were comparable with those in the unchallenged
chimeras (Figure 3H, 3I). The absolute numbers of NKT cells and
abT cells (thymocytes) in the organs from various hu-thy/liv-
SCID chimers were shown in the Table S2.
We next performed various RTOC of human fetal DP
thymocytes reaggregated with syngeneic fetal thymic stromal cells
(thymic DC-included), purified thymic DCs, or BM-derived DCs.
Various stimuli (EBV-epitopes, infectious EBV or a-GalCer) were
applied during the culture. The frequency of total NKT cells was
low (,0.01% of RTOC cells) in the EBV- or a-GalCer-challenged
RTOC established with only DP thymocytes (Figure 4B). In
RTOC of DP thymocytes reaggregated with syngeneic fetal
thymic stromal cells (thymic DC-included), purified thymic DCs,
or BM-derived DCs, the EBV-challenge significantly promoted
the generation of total NKT cells. After 14-day-culture, the
frequency of total NKT cells was up to 2.5–2.8% of RTOC cells,
whereas treatment with a-GalCer had no such effect (Figure 4B).
Addition of HLA-matched or unmatched EBV-epitopes
(BMLF1+EBNA1) had no significant effect on the frequency of
total NKT cells (,0.01% of RTOC cells) compared to the un-
stimulated RTOC (Figure 4B and data not shown). In RTOCs
where thymic or BM-derived DCs were present, EBV-challenge
substantially promoted the development of CD8
+ NKT cells. Up
to 25% of NKT cells expressed CD8 in EBV-challenged RTOCs
(Figure 4C). In this case, HLA-matched EBV-epitopes moderately
and significantly increased the development of CD8
+ NKT cells
(2.5% of NKT cells), compared with those in un-stimulated
RTOCs (Figure 4C). In RTOC of DP thymocytes reaggregated
with DC-depleted thymic stromal cells, the EBV-induced increase
in CD8
+ NKT was almost completely abolished (data not shown).
Both the frequency of total mature abTCR-expressing T cells and
the ratio of CD4
+ to CD8
+ T cells in the different RTOC
conditions were comparable (Figure 4B, 4D).
To further confirm that EBV mediated intrathymic CD8-
lineage differentiation of human NKT cells, we focused our
attention on detecting the actual EBV- or HTLV-1-infection of
human progenitor thymocytes, thymic NKT cells and thymic DCs
in the virus exposed hu-thy/liv-SCID chimeras. For detection of
EBV-infection, five transformation-associated EBV-genes, LMP1,
EBNA1, BZLFl, BALF2, and RAZ were examined. By Southern
blot and Q-PCR, a high level of viral genes and mRNA transcripts
were detected in EBV-exposed human DCs in the chimeras. Since
mice are not the natural EBV host and their DCs are well-known
to be unsusceptible to EBV, these results indicated that EBV
infected only the transplanted human DCs in EBV-exposed hu-
thy/liv-SCID chimeras during NKT cell development and
differentiation. There was no evidence of EBV viral genes in
EBV-exposed human chimeric DP thymocytes or mature CD4
+
and CD8
+ NKT cells (Figure S2A). For detection of HTLV-1-
infection, 2 highly conserved viral X-region DNA sequences,
EBV-Induced CD8
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SK43 and SK44 were detected in human chimeric HTLV-1-
exposed DP abTCR-expressing T cells (Figure S2B) as well as in
chimeric hepatic T cells (data not shown). There was no detectable
HTLV-1 in thymic CD4
+ and CD8
+ NKT cells or in DCs in the
HTLV-1-exposed hu-thy/liv-SCID chimeras, indicating that
HTLV-1 virus does not correlate with NKT cell differentiation
in EBV-exposed hu-thy/liv-SCID chimeras.
EBV-induced CD8
+ NKT cell development is IL-7-
dependent
IL-7 and IL-15 were known survival factors for T cells, and
enhancers of NKT cell homeostatic proliferation [21,26,38,39].
Both cytokines were used in attempts to differentiate and activate
NKT cells from human peripheral and cord blood [35,40,41]. DP
thymocytes expressed an increased level of IL-7Ra in EBV-
challenged hu-thy/liv-SCID chimeras compared to unchallenged
chimeras. The thymic DCs produced a considerable amount of
IL-7 mRNA in unchallenged chimeras, and the levels increased
substantially with EBV-challenge (Figure S3A). The thymic CD8
+
NKT cells expressed a very high level of IL-7Ra mRNA in EBV-
challenged hu-thy/liv-SCID chimeras compared with other types
of thymic NKT cells and abTCR-expressing T cells in both
unchallenged and EBV-challenged chimeras (Figure S3A). The
thymic DCs produced a considerable amount of IL-15 mRNA in
both unchallenged and EBV-challenged chimeras. The thymic
CD4
+ and DN NKT cells expressed higher levels of IL-15Ra
mRNA in both unchallenged and EBV-challenged hu-thy/liv-
SCID chimeras compared with other types of thymic NKT cells
and abTCR-expressing T cells in both chimeras (Figure S3A). In a
time course study, the freshly isolated fetal thymic DCs were found
to express a low level of IL-7 mRNA. Thymic DCs in
unchallenged chimeras expressed comparable levels of IL-7
mRNA at the different time intervals examined, 1, 3, and 5
weeks. By contrast, the thymic DCs rapidly increased the
expression of IL-7 mRNA by week 1 post-EBV challenge, and
maintained high levels throughout the course of the analysis
(Figure S3B). The IL-15 mRNA was uniformly expressed in the
thymic DCs of both unchallenged and EBV-challenged chimeras
(Figure S3B). Thymic stromal cells (DC-depleted) expressed a
uniformly low level of IL-7 and IL-15 mRNA in both
unchallenged and EBV-challenged chimeras (data not shown).
These observations on cytokine and cytokine receptor mRNA
expression were confirmed at the protein level by intracellular flow
cytometry (for IL-7 and IL-15) and conventional flow cytometry
Figure 3. EBV-induced CD8
+ NKT cell development occurs at
the DP thymocyte stage and depends upon thymic dendritic
cells. (A) The experimental and analysis scheme for detecting co-
receptor-expressing NKT cells and T cells in various organs from
different hu-thy/liv-SCID chimeras is illustrated after collecting 2.0610
6
total cell events. (B–I) Development of co-receptor-expressing NKT cells
(middle panels) and T cells (right panels). Data illustrate the frequency
of co-receptor-expressing NKT cells and T cells in thymus, liver and
spleen from EBV-challenged hu-thy/liv-SCID chimeras (EBV). Unchal-
lenged hu-thy/liv-SCID chimeras (Nil) were used as controls. The
protocols for the establishment of the various hu-thy/liv-SCID chimeras
were described in the leftmost panels. (B–G) Instead of total
thymocytes, hu-thy/liv-SCID chimeras were established by intrathymic
transplantation with DP thymocytes. The chimeras were sacrificed at
the indicated time points following post-immune-reconstitution and
viral challenge. Staining was performed as in Figure 2. +DC, thymic DCs
were included. -DC, thymic DCs were depleted. In (H) and (I) the hu-thy/
liv-SCID chimeras were established by intrathymic transplantation with
DP thymocytes. Instead of transplantation with thymic stromal cells,
BM-derived dendritic cells (1610
6 cells) were injected i.v. into the hu-
thy/liv-SCID chimeras at t=0. VL, very low level (below detectable level).
ND, no determination. Data (B–I) were mean 6 s.d. (n = 8). *, p,0.001,
EBV-challenged chimeras vs. non-challenged chimeras.
doi:10.1371/journal.ppat.1000915.g003
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are a major source of IL-7 during the thymus-dependent
development of NKT cells.
The frequency of total NKT cells were low (,0.01% of FTOC
cells) after 14-days of culture without adding any stimuli in FTOC
(Figure5B).NearlyalloftheNKTcellswereCD4-positiveandCD8
+
cells were undetectablein these conditions (Figure 5C). By contrast, in
FTOC with added EBV, the frequency of total NKT cells was
increased (1.5% of FTOC cells), and of these, 15% of cells expressed
CD8, whereas, in FTOC with added HLA-matched EBV-epitopes,
neither total nor CD8
+ NKT cells were changed (,0.01% of FTOC
cells, of which ,1% were CD8
+) (Figure 5C). Exogenous IL-7 or IL-
15 alone slightly but significantly increased the total, but not CD8
+
NKT cell differentiation in the FTOCs (,0.01% of FTOC cells)
(Figure 5C). HLA-mismatched EBV-epitopes were non-functional in
FTOCs (data not shown). In EBV-challenged FTOCs, exogenous IL-
7, but not IL-15, could significantly further enhance the total and
CD8
+NKTcelldifferentiation(,2.5% of FTOC cells,of which20%
were CD8
+), compared to the EBV-challenged but non-IL-7-
stimulated FTOC and un-stimulated FTOC (Figure 5B, 5C). A
mAb against IL-7 completely abolished the effect of IL-7 on the
differentiation of CD8
+ NKT cells in the EBV-challenged FTOCs,
indicating an essential role of the cytokine in the differentiation of
CD8
+ NKT cells. In FTOCs containing added a-GalCer, IL-7
slightly enhanced total, but not CD8
+ NKT celldifferentiation (,1%
of FTOC cells, of which ,0.8% were CD8
+)( F i g u r e5 B ,5 C ) .T h e
mAb against IL-7 completely inhibited the effect of IL-7 on the
differentiation of total NKT cells in the FTOCs stimulated with a-
GalCer. IL-15 had no such effect on the development of total NKT
cells in the FTOCs stimulated with a-GalCer. The frequency of total
matureabTCR-expressing T cells,but not ratios of CD4
+to CD8
+T
cells, was enhanced by IL-7 or/and IL-15 in the various FTOCs
(Figure 5B, 5C).
Consistent with the above in vitro findings in the FTOCs,
administration of exogenous IL-7 further enhanced development
of thymic and hepatic total and CD8
+ NKT cells in the in vivo
EBV-challenged hu-thy/liv-SCID chimeras (Figure 6B), compared
to chimeras given exogenous IL-7 but not EBV (data not shown)
and to EBV-challenged chimeras not treated with exogenous IL-7
(Figure 2E). The frequency of total NKT cells was significantly
increased (,3.8% of thymic and ,3.2% hepatic cells) (Figure 6B).
About 28% of thymic and hepatic NKT cells expressed CD8
(Figure 6B and Table S2). The administration of mAb against IL-7
(plus exogenous IL-7) completely blocked the function of IL-7 in
vivo (Figure 6C and Table S2), indicating an essential role of the
cytokine in the EBV-induced development of CD8
+ NKT cells.
The administration of exogenous IL-7 plus isotype-matched
control Ab had no the blocking effect (Figure 6D and Table S2).
Thus, EBV-induced increase in CD8
+ NKT cell development is
IL7-dependent.
To track NKT cellsmore accurately, weapplied6B11mAb, which
recognized TCR Va24JaQ junction CDR3-loop, combined with
mAb against Va24TCR for gate of NKT cells by flow cytometry.
The outcome of frequencies of total and co-receptor-expressing NKT
cellsgated by eitherCD1d tetramersvs. anti-abTCR mAb or by anti-
Va24 mAb vs. 6B11 mAb were comparable in different human
normal subjects or EBV-infected patients (Figure S4A). Comparable
sets of data on frequencies of total and co-receptor-expressing NKT
cells were also obtained in thymus and liver from EBV-challenged
hu-thy/liv-SCID chimeras (Figure S4B), as well as in EBV-exposed
RTOCs and FTOCs (data not shown), gated by either CD1d
tetramers vs. anti-abTCR mAb or anti-Va24 mAb vs. 6B11 mAb by
flow cytometry. These data confirmed the observations on EBV-
induced development of CD8
+ NKT cells, and ruled out possible
contamination of activated conventional CD8
+ T cells during the
flow cytometry analysis.
EBV-induced CD8
+ NKT cells produce abundant perforin
In our recent study [42], frequencies of CD8
+ NKT cells in
patients with EBV-associated malignancies were found signifi-
cantly lower than those in healthy EBV carriers. CD8
+ NKT cells
in tumor patients were functionally impaired in terms of cytokine
production and cytotoxicity. In hu-thy/liv-SCID chimeras, EBV-
exposure efficiently augmented the generation of IFN-c-biased
CD8
+ NKT cells, which were strongly cytotoxic to EBV-associated
tumor-cells. IL-4-biased CD4
+ NKT cells were predominately
generated in unchallenged chimeras, which were non-cytotoxic. In
tumor-transplanted hu-thy/liv-SCID chimeras, adoptive transfer
with EBV-induced CD8
+ NKT cells remarkably suppressed
tumorigenesis by EBV-associated malignancies. CD4
+ NKT cells
were synergetic with CD8
+ NKT cells, leading to a more
pronounced T-cell anti-tumor response in the chimeras co-
transferred with CD4
+ and CD8
+ NKT cells. In the present
study, we further investigated the perforin expression in NKT cells
(Figure 7). CD8
+ NKT cells from healthy EBV
+ humans, EBV-
challenged hu-thy/liv-SCID chimeras, or EBV-exposed RTOCs
and FTOCs produced much higher amount of perforin (Figure 7B)
than that in counterpart CD4
+ NKT cells (Figure 7A), indicating
that high production of perforin in EBV-induced CD8
+ NKT cells
was an additional reason for their high cytotoxicity to EBV-
associated tumor cells, besides their biased IFN-c-production [42].
In the analysis, we applied flow cytometry using the gating of
either CD1d tetramers vs. anti-abTCR mAb and anti-Va24
mAb vs. 6B11 mAb. Two groups of results were comparable
(Figure 7).
Moreover, we further analyzed the CD8a and CD8b expression
on NKT cells. Data revealed that CD8aa homodimer was
predominately expressed on CD8
+ NKT cells in PBMCs from
healthy latent EBV-infected subjects and IM patients at year 1
post-onset, as well as from normal control subjects (Figure 8B and
8C), which were consistent with the previous reports [31]. CD8aa
homodimer was also expressed in the majority of CD8
+ NKT cells
in thymus and liver from hu-thy/liv-SCID chimeras challenged i.t.
with EBV (Figure 8D and 8E) and in EBV-exposed RTOCs and
FTOCs (data not shown). In the analysis, we applied flow
cytometry using the gating of either CD1d tetramers vs. anti-
abTCR mAb and anti-Va24 mAb vs. 6B11 mAb. Two groups of
results were comparable (Figure 8).
Discussion
Taken advantage of the hu-thy/liv-SCID chimeric mouse
model [43,44], we have found that a sizable CD8
+ fraction (up
to 25%) of total human thymic NKT cells is generated in vivo after
EBV-challenge. The development of CD8
+ NKT cells is promoted
in the thymus at the DP precursor stage, and requires participation
of thymic DCs. CD4 versus CD8 lineage commitment is
controlled by the EBV-challenge. The findings provide a crucial
access point for unraveling the mechanism for NKT cell
development and differentiation. This study led to two important
insights. First, we provide direct evidence that certain pathogens,
EBV in this case, are important contributors to CD8-lineage
commitment of NKT cells. Second, we demonstrate that
differential CD4 versus CD8 lineage commitment can be
controlled not only by some known classical endogenous elements
[1,2], but also by exogenous pathogenic element(s) such as EBV.
The impact of different viral pathogens on NKT cell frequencies
has been investigated. In humans, infection by HIV and HTLV-1
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long-termlossofNKTcellssinceinductionofapoptosis[53,54].The
patients with severe immunodeficiency (XLP), lacking of NKT cells,
is characterized by an extreme sensitivity to EBV infection [55,56].
Our previous [42] and current works show that EBV-infection
promotes generation of IFN-c- and perforin-biased CD8
+ NKT
cells, and IL-4-biased CD4
+ NKT cells. A protective role of CD8
+
NKT cells synergized with their counterpart CD4
+ NKT cells
against EBV-associated malignancies has been verified. The
beneficial role against the persistence of EBV-infection could be
speculated.Theobservationoninductionofdominatepopulationsof
CD8aa
+ NKT cells by EBV-infection is in agreement with previous
report on that CD8aa
+ NKT cells control expansion of total and
EBV-specific T cells in humans [31], and is supporting the
observation in mice [30].
There remain several controversial issues concerning CD8
+
NKT cell development. For example, why does the frequency of
human CD8
+ NKT cells show such a limited correlation
Figure 4. EBV-induced CD8
+ NKT cell differentiation depends upon thymic dendritic cells. (A) The experimental and analysis scheme for
detecting co-receptor-expressing NKT cells and T cells in various reaggregated fetal thymic organ cultures (RTOCs). After 14-days of culture, the
various cell types were identified by flow cytometry as in Figure 2. (B–D) Frequency of total NKT cells and total T cells (B), co-receptor-expressing NKT
cells (C) and T cells (D), in the different RTOCs. The protocols for the establishment of the RTOCs were described in the leftmost panels in each sub-
figure: DP thymocytes were reaggregated with either total thymic stromal cells (DC-included), purified thymic dendritic cells, or BM-derived dendritic
cells. The stimuli were added as indicated. Nil, no stimulus; EBV-epitopes, HLA-A2-restricted, derived from the lytic cycle protein BMLF1 and HLA-
DRB1-restricted, derived from nuclear antigen EBNA1 (10 mg/ml each); EBV, infectious EBV (10
7 pfu); Solvent, 0.005% polysorbate 20; a-GalCer (0.1 mg/
ml). The RTOCs were harvested, and assessed by flow cytometry. Only the data for CD4
+ and CD8
+ NKT cells, and CD4 SP and CD8 SP T cells were
shown. VL, very low level (below detectable level). Data were mean 6 s.d. (n = 10). *, p,0.001, EBV-challenged RTOCs vs. non-challenged RTOCs.
doi:10.1371/journal.ppat.1000915.g004
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ages (fetus, neonate and adults), and why are CD8
+ NKT cells
the most numerically variable NKT cell subset in humans,
particularly under pathophysiological circumstances [1,2,26–
28,33–37]. In the present study, we were able to monitor the
intrathymic and extrathymic development of human NKT cells
in different organs in hu-thy/liv-SCID chimeric mice. Since all
mature NKT cells were depleted from the thymocytes prior to
cell transplantation (Figure S6), any co-receptor-expressing
human NKT cells detected in the mice should have developed
and differentiated post-cell-transplantation. Since all fetal
samples have been from non-EBV-infected mothers, the EBV-
Figure 5. IL-7 is required for EBV-induced CD8
+ NKT cell differentiation in vitro. (A) The experimental and analysis scheme for detecting co-
receptor-expressing NKT cells and T cells in various human fetal thymic organ cultures. After 14-day-culture, the various cell types were identifiedb yf l o w
cytometry as in Figure 2. (B–D) Frequency of total NKT cells and total T cells (B), co-receptor-expressing NKT cells (C) and T cells (D) in the different FTOCs.
The protocols for the establishment of different FTOCs were described in the leftmost panels in each sub-figure. The various stimuli and blockers were
added as indicated. Nil, no stimulus; EBV-epitopes, HLA-A2-restricted, derived from the lytic cycle protein BMLF1 and HLA-DRB1-restricted, derived from
nuclear antigen EBNA1 (1 mg/ml each); EBV, infectious EBV (10
7 pfu); Solvent,0.005% polysorbate 20;a-GalCer (0.1 mg/ml). IL-7 (10 ng/ml); IL-15 (10 ng/ml),
Abs, either mouse anti-human IL-7 monoclonal Ab plus mouse anti-human IL-7Ra monoclonal Ab, or mouse anti-human IL-15 monoclonal Ab plus mouse
anti-human IL-15Ra monoclonal Ab, respectively (5 mg/ml each); The FTOCs were harvested and assessed by flow cytometry. Only the data for CD4
+ and
CD8
+ NKT cells and CD4 SP and CD8 SP T cells were shown. VL, very low level (below detectable level). Data were mean 6 s.d. (n=10). ** p,0.05. *,
p,0.001, EBV-challenged FTOCs vs. non-challenged FTOCs; IL-7-challenged FTOCs vs. non-challenged FTOCs.
doi:10.1371/journal.ppat.1000915.g005
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effects on the differentiation of CD8
+ NKT cells. Nevertheless,
more evidences are needed to rule out the possibility that EBV is
capable of influencing NKT cell expansion/differentiation in
the periphery.
Given the functional distinction between CD4
+ and CD8
+ NKT
cells [26–28,33–37] and their potential therapeutic importance such
as in cancer treatment [42], it is crucial to identify the factors that
induce the development and differentiation of these cells in order to
fully understand the causes of NKT cell subset deficiency and
dysfunction, particularly of the CD8
+ NKT cells. Some investigators
hold the opinion that the immature NKT cells undergo extrathymic
differentiation in adult blood [27,28,33–37]. Our studies have
demonstrated that the frequency of total NKT cells and the different
subsets in thymus, liver and peripheral blood from unchallenged and
EBV-challenged chimeras is highly correlated, clearly indicating an
intrathymic developmental and differentiation step for human CD8
+
Va24
+NKT cells. Moreover, the hu-thy/liv-SCID chimeras have
provided an in vivo model to investigate cell development and
differentiation of human NKT cells under both physiological and
pathophysiological circumstances.
In mice, IL-15 plays an essential role in the maturation and
overall population size of NKT cells in the thymus and periphery
[21,22,30]. On the other hand, IL-7 is critical for the development
of NKT cells, but plays a minor role in regulating their maturation
and homeostasis [21]. In humans, IL-7 dominates the CD4
+ NKT
cell development process in the fetus, neonate, and adult [26,39],
whereas IL-15 has a selective and age-specific role in vitro in the
expansion and homeostasis of the DN and CD8
+ NKT cell subsets
[27]. We show here that IL-7 is a major and essential enhancer of
EBV-induced development of thymic CD8
+ NKT cells in vivo,i n
the hu-thy/liv-SCID chimeras, and in vitro in FTOCs. We still
need to define the role of IL-7 in the continuous NKT cell division
in the periphery of adults, if it indeed exists, for instance, in
secondary lymphoid organs where IL-7 is available.
Taking the fact that EBV causes asymptomatic life-long
infection in ,90% of adults worldwide into consideration, the
experimental design for developmental studies of NKT cells
should pay special attention to the EBV status of the donors of
any human samples, since we have shown here that EBV-
infection status of the hu-thy/liv-SCID chimeras and the human
donors can directly affect the frequency of total and co-receptor-
expressing populations of NKT cells. More importantly, the
present study has raised several interesting questions, such as how
the semi-invariant canonical abTCR is expressed on DP
thymocyte precursor before commitment to the CD4 versus
CD8 lineage differentiation of NKT cells, as well as what and
how the ligand is presented by thymic DCs to the semi-invariant
abTCR-expressing DP thymocyte precursor causing the prefer-
ential CD8 differentiation.
Figure 6. IL-7 is required for EBV-induced CD8
+ NKT cell development in vivo. (A) The experimental and analysis scheme for detecting co-
receptor-expressing NKT cells and T cells in various organs from hu-thy/liv-SCID chimeras treated with IL-7. The chimeras were established by intrathymic
transplantation with DP thymocytes. The chimeras were treated i.v. with IL-7 (0.1 mg/kg/d), or with IL-7 plus mAb against IL-7 (1 mg/kg/d) (IL-7+Ab), or IL-7
plus isotype Ab(1 mg/kg/d) (IL-7+Iso)asindicated.Thechimerasweresacrificedattheindicatedtimepointsfollowingpost-immune-reconstitutionandviral
challenge. Staining was performed as in Figure 2. (B–D) Development of co-receptor-expressing NKT cells. Data show the frequency of co-receptor-
expressing NKT cells in thymus or livers from hu-thy/liv-SCID chimera challenged i.t. with EBV (EBV), as assessed by flow cytometry. The protocols fort h e
establishment of thechimeras were describedin the leftmost panel. +DC, thymic DCs were included. VL, very low level (below detectable level). Data (B–D)
were mean 6 s.d. (n=7 or 8). *, p,0.001, EBV- and IL-7-challenged chimeras vs. a-IL-7 Ab-treated chimeras.
doi:10.1371/journal.ppat.1000915.g006
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Patients, cells, tetramers, and other reagents
The latent EBV-infected [referred to as EBV
+(La)] or normal
control subjects (NS) were healthy EBV seropositive or
seronegative individuals, respectively. The patients with EBV-
associated acute infectious mononucleosis [lytic phase, referred
to as EBV
+(IMa)] were diagnosed by a monospot test and the
detection of capsid-specific serum IgM [56], and followed-up at
1 year [latent phase, referred to as EBV
+(IMy)]. The patients
with EBV-associated Hodgkin lymphoma (HL) were diagnosed
according to the WHO criteria, and staged according to the
Ann Arbor classification (Table S1). All EBV
+(La) and NS
individuals were healthy volunteers. All patients eligible for this
study were in- or out-patients in different Hospitals in Hubei
Province in China. HLA typing was performed using the
Figure 7. Perforin expression in human and chimeric CD4
+ and CD8
+ NKT cells. PBMC were from healthy latent EBV-infected subjects
[EBV
+(La)], IM patients at year 1 post-onset [EBV
+(IMy)], EBV-associated HL patients [EBV
+(HL)] and EBV-negative normal control subjects (NS). Thymic
cell suspension were from EBV-exposed (EBV
+), un-exposed (EBV
2) or HTLV-1-exposed (HTLV-1
+) hu-thy/liv-SCID chimeras, or from EBV-exposed
(EBV
+) or un-exposed (EBV
2) RTOC and FTOC. For detection of intracellular expression of perforin, cells were stimulated with a-GalCer (1 mg/ml) for
24 hrs, intracellular stained, and assessed by flow cytometry using the experimental strategy shown in the upper panel of each subfigure. The NKT
cells were gated by either CD1d tetramers vs. anti-abTCR mAb (middel panels) or anti-Va24 mAb vs. 6B11 mAb (bottom panels). Perforin positive cells
(%) in gated CD4
+ (A) and CD8
+ (B) NKT cells were shon. Solvent for a-GalCer was 0.005% polysorbate 20 (not shown). Nil, negative stimulation
control. ND, no determination. Data were mean 6 s.d. (n=8). **, p,0.05; *, p,0.001. CD8
+ in (B) vs. counterpart CD4
+ NKT cells in (A).
doi:10.1371/journal.ppat.1000915.g007
EBV-Induced CD8
+ NKT Cell Development
PLoS Pathogens | www.plospathogens.org 11 May 2010 | Volume 6 | Issue 5 | e1000915Lymphotype Class I system (Biotest) and an Olerup SSP kit
(GenoVision). The clinical information of all patients and
healthy EBV-infected and normal control subjects is listed in
Table S1. All patients were newly-diagnosed and had no
previous treatment before entry into this study. All patients
provided informed consent according to the institutional
guidelines and protocol titled ‘‘The study on the frequency
and subset distributions of human peripheral NKT cells in
normal and EBV-infected subjects’’ that was approved by The
Wuhan University Ethical Committee. The written informed
consent from each patients and subjects was obtained.
Human fetal thymic cells, bone marrow (BM) cells, liver and
PBMCs were anonymously obtained from voluntarily elective
pregnancy terminations (,24-wk-gestation; HLA typing matched
HLA-A2 and HLA-DRB1(*03), the most prevalent HLA-types for
Eastern and Southern Chinese populations, and mismatched
HLA-A11, -B8 and HLA-DQ5). The mothers were excluded if
lytic and latent EBV- and HTLV-1-infections were detected by Q-
PCR and serologic determination [57]. Thymic cells, BM cells and
PBMCs were isolated, aliquoted, cryopreserved and maintained in
the vapor phase of liquid nitrogen for further use. Viability of
thawed cells was evaluated by Trypan blue dye exclusion before
use. Thymic dendritic cells were separated from the thymocytes by
adhesion onto plastic culture dishes. For transplantation, NKT
cells were positively depleted from thymic cells by MACS beads
based on staining with a-GalCer-loaded CD1d tetramers [58]. For
functional studies, NKT cells were purified from human PBMCs
or chimeric thymic cells by flow cytometry cell sorting or a MACS
bead system based on staining with a-GalCer-loaded CD1d
tetramers [58,59]. Synthesized peptides (proteins) were EBV-
epitopes, GLCTLVAML (HLA-A2-restricted, derived from the
lytic cycle protein BMLF1), AVFDRKSDAK (HLA-A11-restrict-
ed, derived from nuclear antigen EBNA3B), RAKFKQLL (HLA-
B8-restricted, derived from the lytic cycle protein BZLF1),
TSLYNLRRGTAL (HLA-DRB1-restricted, derived from nuclear
antigen EBNA1), SDDELPYIDPNM (HLA-DQ5-restricted, de-
rived from nuclear antigen EBNA3C) [60]. Recombinant peptides
(proteins) were verified free of pyrogenicity (endotoxin ,10 units/
ml, no bacterial or fungal contamination) according to the
certifications from the manufacturer. The a-GalCer-loaded
CD1d tetramers were synthesized as previously described [58–
60]. For preparation of viral stocks, a highly productive EBV-
Figure 8. NKT cells differentially express the CD8a and CD8b chain. (A) The experimental and analysis scheme for detecting total and co-
receptor CD8a- and CD8b-expressing NKT cells. (B)a n d( C) NKT cells in PBMCs from healthy latent EBV-infected subjects [EBV
+(La)], IM patients at
year 1 post-onset [EBV
+(IMy)], EBV-associated HL patients [EBV
+(HL)] and EBV-negative normal control subjects (NS) were assessed by flow
cytometry using the gate of either CD1d tetramers vs. anti-abTCR mAb (B) or anti-Va24 mAb vs. 6B11 mAb (C). Further dot plot analysis of CD8a
vs. CD8b in gated NKT cells was shown. (D)a n d( E), NKT cells in thymus (Thy) and liver (Liv) from hu-thy/liv-SCID chimeras challenged i.t. with EBV
(EBV
+) or unchallenged (EBV
2) were assessed by flow cytometry using the gate of either CD1d tetramers vs. anti-abTCR mAb (D) or anti-Va24 mAb
vs. 6B11 mAb (E). Further dot plot analysis of CD8a vs. CD8b in gated NKT cells was shown. Data were representatives of 5 similar experiments in
each group.
doi:10.1371/journal.ppat.1000915.g008
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ATCC, Manassas, VA) was treated with 12-O-tetradecanoyl-
phorbol-13-acetate (TPA, 30 ng/ml) for 14 days. The virus was
then pelleted from the culture supernatant. The residual TPA in
the viral suspension for final use had no significant promoting
effect on cell proliferation in the in vivo human-thymus-SCID
chimeras, based on our preliminary experiments. Recombinant
human (rh) IL-7 (Roche) and rhIL-15 were purchased from R&D
Systems. All mouse anti-human monoclonal antibodies were
purchased from BD PharMingen, San Diego, CA, USA, except
mAbs against human Va24 or Vb11, which were from
Immunotech, Marseille, France.
Human-thymus/liver-SCID chimeras
To establish the human-thymus/liver-SCID (hu-thy/liv-SCID)
chimeras, 8-wk-old female SCID mice (NOD/LtSz-prkdc
scid/
prkdc
scid strain, the Jackson Laboratory) were irradiated (300
cGy/mouse) prior to cell-transplantation. Human fetal thymic
cells were depleted of immature and mature NKT cells based on
their reactivity with a-GalCer-loaded CD1d tetramers. Then,
1610
7 thymocytes, thymocytes: thymic stromal cells including
dendritic cells=1:1 (Figure S5), were transplanted into the thymus
of anaesthetized SCID mice [43,44,58,59]. Syngeneic human fetal
liver tissue (equivalent to 1610
7 fetal liver cells) was simultaneously
implanted under the mouse kidney capsule, unless otherwise
noted. The chimeras were then intrathymically challenged with
EBV (10
7 pfu) [60] or HTLV-1 (10
7 pfu), and the challenge was
repeated after 6 days. The chimeras were maintained for 4 wks,
unless otherwise stated [43,44]. In some cases, chimeras were
established by transplantation with human fetal thymic cells
(thymocytes plus thymic stromal cells), but without implantation of
fetal liver tissue referred to as human-thymus-SCID (hu-thy-SCID
chimera). The mice were housed in a pathogen-free environment
in the Animal Research Institute, Wuhan University. The protocol
for animal study titled ‘‘The study on the frequency and subset
distributions of NKT cells in human-thymus/liver-SCID chime-
ras’’ was approved by The Wuhan University Ethical Committee
in accordance with the current Chinese laws.
Fetal thymic organ culture (FTOC) and reaggregated
thymic organ culture (RTOC)
FTOC was carried out as described previously [61]. Briefly,
fetal thymus tissue was dissected into pieces of ,2m m
3. Three
pieces of tissue were placed into 24-well plates with culture
medium containing various stimuli as indicated. On day 7, the
cultured thymus fragment was dispersed into a single-cell
suspension, and cells were stained and analyzed by flow cytometry.
RTOC experiments were performed as previously described [61].
Briefly, thymic stromal cells were prepared by disaggregating fetal
thymic lobes. DP thymocytes were obtained by gently grinding
freshly fetal thymus lobes. The resulting suspensions were sorted
for DP thymocytes using CD4 and CD8 labeling. Reaggregates
were formed by mixing together the desired thymic stromal cells
and DP thymocytes at 1:1 cell ratio with other stimuli as indicated.
After pelleting the cells by centrifugation, the cell mixture was
placed as a standing drop on the upper membrane surface, and
incubated for 5–12 days.
Flow cytometry
The a-GalCer-loaded CD1d tetramer and abTCR (Immuno-
tech, clone BMA031) was used to define total NKT cells. For
tetramer staining, the cells were incubated with the tetramer
labeled with fluorochromes at 37uC for 15 min. The appropriate
isotype Ab (abTCR mAb isotype mouse IgG2b) and empty CD1d
tetramer conjugated with a fluorochrome was used to establish
negative staining gates. The representative experiments for NKT
cell gate negative staining were illustrated in Figure 1 and Figure
S6. The abTCR and other relevant mAbs were used to identify
the different subsets of T cells. In some cases, mAb against human
CDR3 loop of invariant TCR Va24 (6B11, Immunotech) and
mAb against human Va24 (including isotype controls) were used
for gating NKT cells. For analysis of co-receptor-expressing NKT
cells, single cell suspensions were stained with mAbs to human
CD4 and CD8a (R&D Systems, clone 11830 and 37006, isotype
mouse IgG2a and IgG2b), unless otherwise noted. In some cases,
NKT cells were stained with mAbs to CD8a and CD8b (Abcam,
clone 2ST8.5H7, isotype mouse IgG2a), simultaneously. In
intracellular staining for detection of perforin, different cells were
resuspended in cold Dulbecco’s PBS, and then permeabilized by
Cytofix/Cytoperm solution (15 min, 4uC, in the dark; BD
Pharmingen) according to the manufacturer’s protocol. These
permeabilized cells were stained with mAb specific for human
perforin (FITC-conjugated G9, mouse IgG2b, BD Pharmingen), or
isotype control, and analyzed by flow cytometry. All analyses were
performed with a FACSCalibur (BD Biosciences). Four- and five-
color analysis was done using CellQuest software.
Real time quantitative RT-PCR (Q-PCR)
All Q-PCR reactions were performed as described elsewhere
[62]. Briefly, total RNA from purified cells (1610
4, purity .99%)
or cell lines was prepared by using Quick PrepH total RNA
extraction kit (Pharmacia Biotech) according to the manufacturer’s
instructions. RNA was reverse transcribed by using oligo (dT)12-18
and Superscript II reverse transcriptase (Life Technologies, Grand
Island, USA). The real time quantitative PCR was performed in
special optical tubes in a 96 well microtiter plate (Applied
Biosystems, Foster City, CA) with an ABI PRISMH 7700
Sequence Detector Systems (Applied Biosystems). By using the
SYBRH Green PCR Core Reagents Kit, fluorescence signals were
generated during each PCR cycle via the 59 to 39 endonuclease
activity of AmpliTaq Gold to provide real time quantitative PCR
information. Primers used in Q-PCR are listed in Table S3.
Statistical analysis
Statistical analyses were performed using the Student9s t test.
Values of p,0.05 were considered statistically significant.
Supporting Information
Figure S1 EBV-induced in vivo CD8
+ NKT cells are mature and
activated. Data showed the expression of CD69, CD45RO,
CD62L, and CD161 on co-receptor-expressing NKT cells (A) and
T cells (B) in thymus from the unchallenged (EBV
2) or EBV
challenged (EBV
+) hu-thy/liv-SCID chimeras, as assessed by flow
cytometry. The chimeras were sacrificed at week 5 of post-
immune-reconstitution and viral challenge. The various organs
and tissues were collected. The experimental and analysis scheme
was illustrated in Figure 2. Empty fluorochrome conjugated CD1d
tetramers were used as a staining control. ND, no determination
since too few cells were detected. Data were representative of each
of 5 sets of experiments conducted (n=7).
Found at: doi:10.1371/journal.ppat.1000915.s001 (0.33 MB PDF)
Figure S2 EBV- or HTLV-1-infection of T cells, thymic NKT
cells and dendritic cells from hu-thy/liv-SCID chimeras. The
chimeras were challenged with either EBV (+) or HTLV-1 (+) for 4
weeks as described in M&M, or left un-challenged (2). The
animals were then sacrificed. Human fetal primary (Prim.)
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cells (DCs) in hu-thy/liv-SCID chimeras were purified according
to the abTCR and co-receptor expression, i.e. CD4
+CD8
+ (DP),
CD4
2CD8
2 (DN), CD4
+ and CD8
+ cells. The different purified
cells were washed extensively after purification. (A) Southern blot
(top panel) and Q-PCR (bottom panel) analyses for detections of
various EBV genomic DNA and mRNA transcripts, respectively.
The primers and probes used were shown in Table S3. The
applied methods were detailed in the references listed below
[63,64]. The EBV-transformed Raji B cell line (EBV
+ B cell line)
was used as a positive control. Data were representative (each
n=6). ND, no determination since too few cells harvested. For
simplification, Q-PCR data from various cells were only shown for
the representative EBV-exposed NP thymocytes, EBV-exposed
CD4
+ and CD8
+ NKT cells, and EBV-exposed DCs. (B) Q-PCR
detection of HTLV-1-infection in genomic DNA extract from
various cells from HTLV-1-exposed (+) hu-thy/liv-SCID chimeras
as described above. The HTLV-1 primer sets were designed
corresponding to the highly conserved HTLV-1 pX region,
referred to as SK43 (top panel) and SK44 (bottom panel) [65,66].
The HTLV-1-infected T-cell lymphoma cell line HUT102
(HTLV-1
+ T cell line) was used as a positive control. ND, no
determination since too few cells harvested. Data were mean 6
s.d. (n=6).
Found at: doi:10.1371/journal.ppat.1000915.s002 (0.41 MB PDF)
Figure S3 EBV-challenge up-regulates IL-7 expression in
thymic dendritic cells. (A) Expression of IL-7, IL-7 receptor alpha
chain (IL-7Ra) (top panels), IL-15, and IL-15 receptor alpha chain
(IL-15Ra) (bottom panels) mRNAs in different thymic cells. The
hu-thy/liv-SCID chimeras were established by i.t. challenge with
EBV (EBV
+). Unchallenged hu-thy/liv-SCID chimeras (EBV
2)
were used as controls. The chimeras were sacrificed at week 5
post-immune-reconstitution and viral challenge. The indicated cell
types were isolated and IL-7, IL-7Ra, IL-15, and IL-15Ra mRNA
levels were assessed by Q-PCR. Data were mean 6 s.d. (n=8). *,
p,0.001. (B) The time course study of IL-7 and IL-15 mRNA
expression in thymic dendritic cells in different chimeras. The hu-
thy/liv-SCID chimeras were established by i.t. challenge with
EBV (EBV
+). Unchallenged hu-thy/liv-SCID chimeras (EBV
2)
were used as a control. The chimeras were sacrificed at the
indicated time points following immune-reconstitution and viral
challenge. IL-7 and IL-15 mRNA levels were assessed by Q-PCR.
Data were mean 6 s.d. (n=9). *, p,0.001, EBV-challenged
chimeras vs. non-challenged chimeras.
Found at: doi:10.1371/journal.ppat.1000915.s003 (0.13 MB PDF)
Figure S4 Comparison among the outcomes of the frequencies
of NKT cell subsets using two different gating staining by flow
cytometry. The comparison was carried out between the
counterpart frequencies of total and co-receptor-expressing NKT
cells gated by either CD1d tetramers vs. anti-abTCR mAb or by
anti-Va24 mAb vs. 6B11 mAb (anti-iTCR Va24JaQ junction
CDR3-loop). (A) The experimental and analysis scheme for
detecting total and co-receptor-expressing NKT cells in PBMC
was illustrated in upper panel. Frequencies of total (left subfigures)
and co-receptor-expressing (right subfigures) NKT cells in PBMCs
from healthy latent EBV-infected subjects [EBV
+(La)], newly-
onset acute infectious mononucleosis patients [EBV
+(IMa)], IM
patients at year 1 post-onset [EBV
+(IMy)], EBV-associated HL
patients [EBV
+(HL)] and EBV-negative normal control subjects
(NS) were assessed by flow cytometry using the gating by either
CD1d tetramers vs. anti-abTCR mAb (middle panels) or anti-
Va24 mAb vs. 6B11 mAb (bottom panels). Data were mean 6 s.d.
(n=4). *, p,0.001. EBV
+(La) or EBV
+(IMy) vs, EBV
+(IMa), NS
or EBV
+(HL). (B) The experimental and analysis scheme for
detecting total and co-receptor-expressing NKT cells in thymus
and liver was illustrated in upper panel. The frequencies of NKT
cells in thymus and liver from hu-thy/liv-SCID chimeras
challenged i.t. with EBV were assessed by flow cytometry at the
indicated timepoints using the gating by either CD1d tetramers vs.
anti-abTCR mAb (left panel) or anti-Va24 mAb vs. 6B11 mAb
(right panel). Data were mean 6 s.d. (n=4). *, p,0.001. EBV
+ vs.
EBV
2 hu-thy/liv-SCID chimeras.
Found at: doi:10.1371/journal.ppat.1000915.s004 (0.75 MB PDF)
Figure S5 Frequency of Va24
+Vb11
+ NKT cells. The frequen-
cy of immature and mature Va24
+Vb11
+ NKT cells in human
fetal thymic cells as assessed by flow cytometry (A) and the ratio of
rearranged Va24-Ja18 and Ca DNAs in fetal thymocytes by Q-
PCR (B) were examined before and after the positive depletion
procedure [58,59]. In A, thymic cells were stained with Va24 and
Vb11 mAbs (left panels) or CD1d tetramer and TCRb (right
panels), respectively. Data were representative of three experi-
ments or mean 6 s.d. *, p,0.001.
Found at: doi:10.1371/journal.ppat.1000915.s005 (0.15 MB PDF)
Figure S6 The staining control data. For accurate quantitation
of NKT cells, cells were stained with fluorochrome conjugated
empty CD1d tetramers (eCD1d tetramer) and abTCR isotype
mAb (abTCRIso) to establish the gate for negative controls. Cells
were from the thymus and liver of EBV-exposed (A) or HTLV-1-
exposed (B) hu-thy/liv-SCID chimeras at week 4 post-challenge as
representatives for in vivo hu-thy/liv-SCID mouse experimental
models. pt, post-transplantation. Other cells were from EBV-
exposed RTOC (C) and FTOC (D) as representatives for in vitro
experimental models.
Found at: doi:10.1371/journal.ppat.1000915.s006 (0.30 MB PDF)
Table S1 Clinical information of normal control and latent
EBV-infected individuals, and patients with IM or HL.
Found at: doi:10.1371/journal.ppat.1000915.s007 (0.13 MB PDF)
Table S2 The absolute numbers of NKT cells and abT cells
(thymocytes) in different organs in various hu-thy/liv-SCID
chimers.
Found at: doi:10.1371/journal.ppat.1000915.s008 (0.13 MB PDF)
Table S3 The sequences of primers and probes for mRNA and
DNA detection in Q-PCR and Southern blot assays.
Found at: doi:10.1371/journal.ppat.1000915.s009 (0.11 MB PDF)
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